CYP4A11/CYP4F2-IN-1
CAS No. 502654-40-2
CYP4A11/CYP4F2-IN-1( —— )
Catalog No. M36462 CAS No. 502654-40-2
CYP4A11/CYP4F2-IN-1 is a cytochrome P450 (CYP) 4A11 and CYP4F2 inhibitor, applicable for research on kidney, cardiovascular, and cerebrovascular diseases.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 121 | In Stock |
|
| 5MG | 202 | In Stock |
|
| 10MG | 297 | In Stock |
|
| 25MG | 502 | In Stock |
|
| 50MG | 699 | In Stock |
|
| 100MG | 918 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | 1841 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameCYP4A11/CYP4F2-IN-1
-
NoteResearch use only, not for human use.
-
Brief DescriptionCYP4A11/CYP4F2-IN-1 is a cytochrome P450 (CYP) 4A11 and CYP4F2 inhibitor, applicable for research on kidney, cardiovascular, and cerebrovascular diseases.
-
DescriptionCYP4A11/CYP4F2-IN-1 is a potent dual inhibitor of cytochrome P450 (CYP) 4A11 and CYP4F2, with IC50s of 19 nM and 17 nM, respectively. CYP4A11/CYP4F2-IN-1 has potential for the research of renal diseases.
-
In VitroCYP4A11/CYP4F2-IN-1 (compound 2) inhibits 20-Hydroxyeicosatetraenoic acid (20-HETE) production from arachidonic acid in human renal microsomes, with an IC50 of 4.2 nM.
-
In Vivo——
-
Synonyms——
-
PathwayMetabolic Enzyme/Protease
-
TargetP450
-
RecptorP450
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number502654-40-2
-
Formula Weight285.36
-
Molecular FormulaC15H15N3OS
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESN1=CSC(=C1C)CCOC=2C=CC(=CC2)C3=NNC=C3
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
TP0472993
CYP4A11/CYP4F2-IN-2 is a potent and orally active dual inhibitor of cytochrome P450 (CYP) 4A11 and CYP4F2, with IC50 values of 140 nM and 40 nM, respectively.
-
Epimedin A1
Epimedin A1(Hexandraside F) is a flavonoid extracted from Herba Epimedii which is one of commonly used Chinese medicines.
-
Rhodionin
Rhodionin and rhodionin can inhibit cytochrome P450 2D6 non-competitively with high specificity which could have implications for interactions with co-administered drugs; they can significantly suppress the elevation of the postprandial blood triglyceride level suggests that they may be to the treatment of lifestyle-related diseases such as hyperlipidemia and exogeneous obesity and to health foods.
Cart
sales@molnova.com